Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS).
Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score
Cystic fibrosis
Lung function
Pulmonary exacerbations
Journal
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
ISSN: 1873-5010
Titre abrégé: J Cyst Fibros
Pays: Netherlands
ID NLM: 101128966
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
19
02
2019
revised:
17
04
2019
accepted:
13
05
2019
pubmed:
28
5
2019
medline:
11
11
2020
entrez:
26
5
2019
Statut:
ppublish
Résumé
Pulmonary exacerbations (PEx) in cystic fibrosis (CF) patients reduce quality of life. Lung function, measured by the percent predicted forced expiratory volume in 1 s (ppFEV1), is widely used to evaluate PEx treatments. We analyzed the correspondence of ppFEV1 with 8 patient-reported symptom-based questions from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS). Data were derived from the observational Standardized Treatment of Pulmonary Exacerbations (STOP) study. CF patients who had CFRSD-CRISS and ppFEV1 measurements on ≥2 timepoints were included: 1) day of initial PEx, 2) 7 days later, and/or 3) end of PEx. We calculated age-stratified Spearman correlation coefficients and 95% confidence intervals (95% CIs) between the change in ppFEV1 and change in CFRSD-CRISS items from index to day 7 and from index to the end of PEx treatment. Lung function and symptom scores improved by the end of treatment; however, correlations between ppFEV1 and the specific CFRSD-CRISS measures were mostly weak to moderate. An exception was that among patients <18, we observed moderately strong correlations between changes in ppFEV1 and cough severity (r = -0.58 (95% CI: -0.80, -0.21)), mucus quantity (r = -0.51 (-0.77, -0.11)), and wheezing (r = -0.53 (-0.78, -0.14)) from index until end of treatment. As novel treatments are developed for PEx, it is important to ensure that improvement is measured meaningfully. The generally weak associations between patient-reported symptoms and ppFEV1 that we found suggest that these measures capture different aspects of the disease and both metrics are important when evaluating new treatments.
Sections du résumé
BACKGROUND
Pulmonary exacerbations (PEx) in cystic fibrosis (CF) patients reduce quality of life. Lung function, measured by the percent predicted forced expiratory volume in 1 s (ppFEV1), is widely used to evaluate PEx treatments. We analyzed the correspondence of ppFEV1 with 8 patient-reported symptom-based questions from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS).
METHODS
Data were derived from the observational Standardized Treatment of Pulmonary Exacerbations (STOP) study. CF patients who had CFRSD-CRISS and ppFEV1 measurements on ≥2 timepoints were included: 1) day of initial PEx, 2) 7 days later, and/or 3) end of PEx. We calculated age-stratified Spearman correlation coefficients and 95% confidence intervals (95% CIs) between the change in ppFEV1 and change in CFRSD-CRISS items from index to day 7 and from index to the end of PEx treatment.
RESULTS
Lung function and symptom scores improved by the end of treatment; however, correlations between ppFEV1 and the specific CFRSD-CRISS measures were mostly weak to moderate. An exception was that among patients <18, we observed moderately strong correlations between changes in ppFEV1 and cough severity (r = -0.58 (95% CI: -0.80, -0.21)), mucus quantity (r = -0.51 (-0.77, -0.11)), and wheezing (r = -0.53 (-0.78, -0.14)) from index until end of treatment.
CONCLUSIONS
As novel treatments are developed for PEx, it is important to ensure that improvement is measured meaningfully. The generally weak associations between patient-reported symptoms and ppFEV1 that we found suggest that these measures capture different aspects of the disease and both metrics are important when evaluating new treatments.
Identifiants
pubmed: 31126901
pii: S1569-1993(19)30113-4
doi: 10.1016/j.jcf.2019.05.009
pmc: PMC6868291
mid: NIHMS1033493
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
886-893Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK089507
Pays : United States
Informations de copyright
Copyright © 2019 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Références
Rev Port Pneumol (2006). 2015 Jul-Aug;21(4):198-202
pubmed: 25926243
Chest. 2004 Jan;125(1 Suppl):1S-39S
pubmed: 14734689
Am J Respir Crit Care Med. 2010 Sep 1;182(5):627-32
pubmed: 20463179
J Cyst Fibros. 2019 Mar;18(2):251-264
pubmed: 30170756
Cochrane Database Syst Rev. 2018 Sep 06;9:CD001127
pubmed: 30187450
Med J Aust. 2011 Oct 3;195(7):392-5
pubmed: 21978346
N Engl J Med. 2017 Nov 23;377(21):2013-2023
pubmed: 29099344
Clinics (Sao Paulo). 2018 Oct 18;73:e427
pubmed: 30365823
Am J Psychol. 1987 Fall-Winter;100(3-4):441-71
pubmed: 3322052
J Cyst Fibros. 2017 Sep;16(5):592-599
pubmed: 28460885
J Cyst Fibros. 2009 Jul;8(4):245-52
pubmed: 19481983
Front Pediatr. 2018 Sep 04;6:244
pubmed: 30234080
J Cyst Fibros. 2017 Sep;16(5):607-615
pubmed: 28438499
J Clin Nurs. 2019 Jan;28(1-2):190-200
pubmed: 30091490
Thorax. 2007 Apr;62(4):360-7
pubmed: 17387214
Malawi Med J. 2012 Sep;24(3):69-71
pubmed: 23638278
Thorax. 2016 Mar;71(3):223-9
pubmed: 25911223
Eur Respir J. 2015 Oct;46(4):1055-64
pubmed: 26160868
CBE Life Sci Educ. 2016 Winter;15(4):
pubmed: 27856555
J Cyst Fibros. 2017 Sep;16(5):600-606
pubmed: 28457954
Psychol Bull. 1968 Oct;70(4):213-20
pubmed: 19673146
Chest. 2005 Oct;128(4):2347-54
pubmed: 16236893
Curr Med Res Opin. 2017 Apr;33(4):667-674
pubmed: 28058864